Global Head of Pharmacovigilance

Be part of our team

The Global Head of Pharmacovigilance in Clinical Development is a strategic leadership role responsible for guiding safety strategy, ensuring compliance, and driving successful trial conduct for Tubulis assets across all stages of development. This leader will direct safety strategy, operations, and regulatory compliance for oncology drug products across clinical development and commercialization phases. This leadership role is central to ensuring safe, compliant, and successful oncology drug development and to maximizing patient safety from clinical trials to post-marketing surveillance.
This position will report to the Chief Medical Officer and be based in Munich, Germany or possible remote opportunities within other locations within Germany.

Your mission

Develop and execute the overall drug safety and pharmacovigilance (PV) strategy aligned with company and global regulatory requirements, especially for oncology assets.Oversee safety surveillance, signal detection, risk assessment, and risk mitigation for investigational and marketed oncology products.Ensure compliance with international PV regulations (FDA, EMA, ICH), SOPs, and best industry practices.Lead and build high-performing PV teams, including medical safety experts and regulatory specialists, fostering a collaborative and high-performance culture.Medical oversight of safety data, including the review of case safety reports (SAEs, SUSARs) and aggregate analyses.Establish and maintain risk management plans, safety monitoring plans, data exchange agreements, and readiness for health authority inspections.Represent the company in safety-related interactions with regulatory agencies, partners, and external stakeholders.Collaborate cross-functionally with clinical development, regulatory, medical affairs, and other teams integrating safety across the product lifecycle.

Your profile

Medical Doctor (MD, MBBS, DO) or equivalent clinical degree.12–15+ years in drug safety/pharmacovigilance with at least 5 years at a senior leadership level in biotech and pharma, Oncology experience is required.Experience with Antibody Drug Conjugates (ADCs) is a strong plus.In-depth knowledge of global PV regulations and experience with safety and efficacy submissions (IND, BLA, NDA, MAA).Experience with risk management plans, signal detection, aggregate safety data review, and case managementHistory of building, leading, and mentoring multidisciplinary teams.Familiarity with major safety databases (eg Argus), coding dictionaries (MedDRA), and digital safety systemsOutstanding communication skills and proven ability to influence, collaborate, and present safety strategy to senior leaders and regulatory authorities.Strategic decision-making abilities and the capacity to oversee budgets, resources, and department objectives in a dynamic environmentFluency in English.

Why us?

At Tubulis, curiosity and innovation drive us to transform cancer treatment. We are a fast-growing biotech where science meets passion—and where you have the chance to grow with us.
Impact that matters: Contribute to breakthrough therapies.Global mindset: Work in an international, diverse team.Grow & thrive: Develop your career in a supportive, fast-moving environment.Innovation every day: Push boundaries with cutting-edge science. At Tubulis, your ideas matter, your growth matters—and together, we make a difference.

About us

The development of novel, effective and safe therapies for the treatment of cancer is one of the main challenges for modern medicine. We want to drive this process forward. The main goal of Tubulis is to become a leading company in the field of targeted therapeutics and antibody-drug conjugates (ADCs). With a strong team, our own technologies and innovative therapeutic concepts, we are ushering in a new era in the ongoing fight against cancer and share the vision of helping patients world-wide. Be part of a multidisciplinary and focused team, that works towards getting novel promising ADCs to patients with solid and hematological cancers.

---